Product Description
Lactobacillus salivarius CECT5713 isolated from breast milk
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Puleva Biotech
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Infertility|Abortion, Spontaneous
Phase 1: Vision, Low
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PROBIFERT P051 | N/A |
Completed |
Infertility |
2023-05-03 |
|
| PROBIFERT P051 | N/A |
Active, not recruiting |
Infertility|Abortion, Spontaneous |
2023-05-03 |
|
| PREPROBIFERT01 | P2 |
Completed |
Infertility|Abortion, Spontaneous |
2019-11-29 |
|
| P010 | P1 |
Completed |
Vision, Low |
2007-09-01 |